ArticleFrontiers in public health2022

Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China.

Zhiyuan Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.